Loading stock data…
Bionano Genomics, Inc. (BNGO)
$1.20-0.00 (-0.42%)
Market OpenUpdated 12:47 PM EDT
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bionano Genomics, Inc. in the Healthcare sector is trading at $1.20 with a market capitalization of $13M. Wall Street consensus targets $5.00 (2 analysts), implying a +316.7% move over the next 12 months. The stock is currently near its 52-week low of $1.00, remaining 6.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +316.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.69M↓ | $7.95M↑ | $7.37M↑ | $6.73M↑ | $6.46M |
| Gross Profit | $3.25M↓ | $3.40M↑ | $3.37M↓ | $3.48M↑ | $2.94M |
| Operating Income | -$7.90M↑ | -$8.54M | -$8.54M↓ | -$7.80M↑ | -$8.46M |
| Net Income | -$8.30M↓ | -$7.93M↑ | -$8.50M↓ | -$6.86M↓ | -$3.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.34%
Volume
Today's trading volume
57,997
Recent News
Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript
Flow cell sales surged 27% as OGM adoption accelerates globally.
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ...
Bionano Genomics Inc (BNGO) reports 21% revenue growth in Q2 2026, driven by record flow cell sales and improved gross margins, while navigating supply constraints and liquidity concerns.
Bionano Genomics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Bionano Genomics, Inc.'s Q2 2026 earnings call
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.